AI Article Synopsis
- Esophageal adenocarcinoma (EAC) is rapidly increasing in the U.S., and a rat model simulating gastroesophageal reflux shows that LTA4H, an inflammatory enzyme, is overexpressed in both rat and human EAC tissues.
- The study utilized western blotting and an LTA4H inhibitor, bestatin, to examine its role in cancer development, finding significant inhibition of LTB4 and a reduced incidence of EAC in treated rats.
- These findings suggest that LTA4H overexpression might be an early indicator of EAC and could be a promising target for chemoprevention strategies.
Article Abstract
Background: Esophageal adenocarcinoma (EAC) is increasing at the most rapid rate of any cancer in the United States. An esophagogastroduodenal anastomosis (EGDA) surgical model in rats mimics human gastroesophageal reflux and results in EAC. Leukotriene A4 hydrolase (LTA4H), a protein overexpressed in EAC in this model, is a rate-limiting enzyme in the biosynthesis of leukotriene B4 (LTB4), a potent inflammatory mediator. We used this model and human EAC and non-tumor tissues to elucidate the expression pattern of LTA4H and to evaluate it as a target for chemoprevention.
Methods: LTA4H expression was examined by western blotting and immunohistochemistry. The functional role of LTA4H in carcinogenesis was investigated by use of an LTA4H inhibitor, bestatin, in the rat EGDA model. All statistical tests were two-sided.
Results: LTA4H was overexpressed in all 10 rat EACs examined, compared with its level in normal rat tissue; it was also overexpressed in four of six human EAC tumor samples, compared with its level in adjacent non-tumor tissue. In tissue sections from 20 EGDA rats and 92 patients (86 with EAC, one with dysplasia, and five with columnar-lined esophagus), LTA4H was expressed in infiltrating inflammatory cells and overexpressed in the columnar cells of preinvasive lesions and cancers, especially in well-differentiated EACs, as compared with the basal cells of the normal esophageal squamous epithelium. Bestatin statistically significantly inhibited LTB4 biosynthesis in the esophageal tissues of EGDA rats (without bestatin = 8.28 ng/mg of protein; with bestatin = 4.68 ng/mg of protein; difference = 3.60, 95% CI = 1.59 to 5.61; P = .002) and reduced the incidence of EAC in the EGDA rats from 57.7% (15 of 26 rats) to 26.1% (6 of 23 rats) (difference = 31.6%, 95% CI = 0.3% to 56.2%; P = .042).
Conclusion: LTA4H overexpression appears to be an early event in esophageal adenocarcinogenesis and is a potential target for the chemoprevention of EAC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jnci/95.14.1053 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
EZH2-mediated suppression of CLDN1 leads to barrier dysfunction in PPI-refractory gastroesophageal reflux disease.
Dig Liver Dis
June 2022
Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address:
Background: PPI-refractory gastroesophageal reflux disease (RGERD) is characterized as the existence of reflux symptoms resistant to optimized PPI treatment. Alleviated mucosal integrity has been regarded as one of the mechanisms of RGERD.
Methods: RNA sequencing analysis and GSEA were performed.
Molecular Profile of Barrett's Esophagus and Gastroesophageal Reflux Disease in the Development of Translational Physiological and Pharmacological Studies.
Int J Mol Sci
September 2020
Department of Physiology, Jagiellonian University Medical College, 31-531 Cracow, Poland.
Barrett's esophagus (BE) is a premalignant condition caused by gastroesophageal reflux disease (GERD), where physiological squamous epithelium is replaced by columnar epithelium. Several in vivo and in vitro BE models were developed with questionable translational relevance when implemented separately. Therefore, we aimed to screen Gene Expression Omnibus 2R (GEO2R) databases to establish whether clinical BE molecular profile was comparable with animal and optimized human esophageal squamous cell lines-based in vitro models.
View Article and Find Full Text PDFInteraction of epidermal growth factor with COX-2 products and peroxisome proliferator-activated receptor-γ system in experimental rat Barrett's esophagus.
Am J Physiol Gastrointest Liver Physiol
March 2020
Department of Physiology, Faculty of Medicine, Jagiellonian University Medical College, Cracow, Poland.
Mixed acidic-alkaline refluxate is a major pathogenic factor in chronic esophagitis progressing to Barrett's esophagus (BE). We hypothesized that epidermal growth factor (EGF) can interact with COX-2 and peroxisome proliferator-activated receptor-γ (PPARγ) in rats surgically prepared with esophagogastroduodenal anastomosis (EGDA) with healthy or removed salivary glands to deplete salivary EGF. EGDA rats were treated with ) vehicle, ) EGF or PPARγ agonist pioglitazone with or without EGFR kinase inhibitor tyrphostin A46, EGF or PPARγ antagonist GW9662 respectively, ) ranitidine or pantoprazole, and ) the selective COX-2 inhibitor celecoxib combined with pioglitazone.
View Article and Find Full Text PDFEsophageal Helicobacter pylori colonization aggravates esophageal injury caused by reflux.
World J Gastroenterol
November 2014
Yun-Xiang Chu, Wei-Hong Wang, Yun Dai, Gui-Gen Teng, Shu-Jun Wang, Department of Gastroenterology, Peking University First Hospital, Beijing 100034, China.
Article Synopsis
- This study aimed to explore how Helicobacter pylori (H. pylori) colonization in the esophagus contributes to damage from acid reflux and the underlying mechanisms.
- An experimental model was created using male rats, which were divided into four groups, including those with and without H. pylori infection, and their esophageal injuries were assessed both macroscopically and microscopically over 36 weeks.
- Results indicated that rats with H. pylori colonization experienced more severe esophageal injuries and higher rates of Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC), along with increased expression of certain proteins linked to intestinal differentiation and cell proliferation.
Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.
J Physiol Pharmacol
August 2010
Department of Physiology, Jagiellonian University Medical College, Cracow, Poland.
Mixed reflux of the gastroduodenal contents induces the esophageal mucosal damage and inflammation progressing chronic esophagitis and premalignant Barrett's esophagus (BE). The role of cyclooxygenase-2 (COX-2) and chronic inflammation in the progression of BE toward adenocarcinoma of the esophagus has not been extensively studied in experimental models of BE in animals and in human subjects. We evaluated the expression of COX-2 in rat model of BE and examined the usefulness of COX-2 expression in determining the risk of malignant transformation in patients with BE treated with argon plasma coagulation (APC) that allows for effective ablation of metaplastic mucosa (group A) without or with proton pump inhibitors (PPI).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!